Genome-Wide Mapping and Interrogation of the Nmp4 Antianabolic Bone Axis
Open Access
- 1 September 2015
- journal article
- other
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 29 (9) , 1269-1285
Abstract
PTH is an osteoanabolic for treating osteoporosis but its potency wanes. Disabling the transcription factor nuclear matrix protein 4 (Nmp4) in healthy, ovary-intact mice enhances bone response to PTH and bone morphogenetic protein 2 and protects from unloading-induced osteopenia. These Nmp4−/− mice exhibit expanded bone marrow populations of osteoprogenitors and supporting CD8+ T cells. To determine whether the Nmp4−/− phenotype persists in an osteoporosis model we compared PTH response in ovariectomized (ovx) wild-type (WT) and Nmp4−/− mice. To identify potential Nmp4 target genes, we performed bioinformatic/pathway profiling on Nmp4 chromatin immunoprecipitation sequencing (ChIP-seq) data. Mice (12 w) were ovx or sham operated 4 weeks before the initiation of PTH therapy. Skeletal phenotype analysis included microcomputed tomography, histomorphometry, serum profiles, fluorescence-activated cell sorting and the growth/mineralization of cultured WT and Nmp4−/− bone marrow mesenchymal stem progenitor cells (MSPCs). ChIP-seq data were derived using MC3T3-E1 preosteoblasts, murine embryonic stem cells, and 2 blood cell lines. Ovx Nmp4−/− mice exhibited an improved response to PTH coupled with elevated numbers of osteoprogenitors and CD8+ T cells, but were not protected from ovx-induced bone loss. Cultured Nmp4−/− MSPCs displayed enhanced proliferation and accelerated mineralization. ChIP-seq/gene ontology analyses identified target genes likely under Nmp4 control as enriched for negative regulators of biosynthetic processes. Interrogation of mRNA transcripts in nondifferentiating and osteogenic differentiating WT and Nmp4−/− MSPCs was performed on 90 Nmp4 target genes and differentiation markers. These data suggest that Nmp4 suppresses bone anabolism, in part, by regulating IGF-binding protein expression. Changes in Nmp4 status may lead to improvements in osteoprogenitor response to therapeutic cues.Keywords
This publication has 71 references indexed in Scilit:
- Mobilization of bone marrow mesenchymal stem cells in vivo augments bone healing in a mouse model of segmental bone defectBone, 2012
- Immortalization and characterization of osteoblast cell lines generated from wild‐type and Nmp4‐null mouse bone marrow stromal cells using murine telomerase reverse transcriptase (mTERT)Journal of Cellular Physiology, 2011
- Nmp4/CIZ Suppresses the Response of Bone to Anabolic Parathyroid Hormone by Regulating Both Osteoblasts and OsteoclastsCalcified Tissue International, 2011
- Time-dependent changes in skeletal response to teriparatide: Escalating vs. constant dose teriparatide (PTH 1–34) in osteoporotic womenBone, 2011
- Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intactJournal of Bone and Mineral Research, 2010
- Thrombospondin-2 regulates matrix mineralization in MC3T3-E1 pre-osteoblastsBone, 2010
- Nmp4/CIZ inhibits mechanically induced β‐catenin signaling activity in osteoblastsJournal of Cellular Physiology, 2010
- T Lymphocytes Amplify the Anabolic Activity of Parathyroid Hormone through Wnt10b SignalingCell Metabolism, 2009
- Nmp4/CIZ suppresses parathyroid hormone‐induced increases in trabecular boneJournal of Cellular Physiology, 2009
- Molecular and cellular mechanisms of the anabolic effect of intermittent PTHBone, 2007